Publications
5255 Results
- Journal / Conference
- International Journal of Cancer Jan 15;152(2):123-136
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID35904874
- PMC
- PMC9691576
- Study Number(s)
- CTSU/C80405
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)
- Journal / Conference
- Leukemia and Lymphoma Feb;64(2):473-477
- Year
- 2023
- Research Committee(s)
- Leukemia
- PMID
- PMID36517990
- Study Number(s)
- S1612
A Randomized Phase II/III Study Of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Age 60 or Older: A Report of the Comparison of Azacitidine and Nivolumab to Azacitidine: SWOG S1612
- Journal / Conference
- Lancet Oncology Feb;24(2):162-174
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID36623515
- PMC
- PMC9924094
- Study Number(s)
- S1416
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
- Journal / Conference
- Journal of Clinical Oncology Jan 17;JCO2201499. doi: 10.1200/JCO.22.01499. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID36649570
- PMC
- https://pubmed.ncbi.nlm.nih.gov/36649570/
- Study Number(s)
- SWOG-8814
Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in the SWOG S8814 trial
- Journal / Conference
- Journal of the National Cancer Institute Jan 10;djad003. doi: 10.1093/jnci/djad003. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Lung
- PMID
- PMID36625510
- Study Number(s)
- S1400I
Quality-of-life outcomes and risk-prediction for advanced lung cancer treated with Nivolumab/Ipilimumab vs Nivolumab
- Journal / Conference
- JCO Precision Oncology Jan;7:e2200372. doi: 10.1200/PO.22.00372.
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID36634296
- PMC
- PMC9928629
- Study Number(s)
- S0500
Tumor-derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer (SWOG S0500)
- Journal / Conference
- JAMA Oncology Jan 26. doi: 10.1001/jamaoncol.2022.6911. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36701146
- Study Number(s)
- CTSU/C80702
Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])
- Journal / Conference
- J Clin Oncol 41, 2023 (suppl 4; abstr TPS265); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA)
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer: SWOG S2107 (NCT05308446)
- Journal / Conference
- Biomarkers Jan 29:1-10
- Year
- 2023
- Research Committee(s)
- Breast
- PMID
- PMID36647745
- Study Number(s)
- S0226
Thymidine Kinase Activity Levels in Serum Can Identify HR+ Metastatic Breast Cancer Patients with a Low Risk of Early Progression (SWOG S0226)
- Journal / Conference
- New England Journal of Medicine Mar 2;388(9):813-823
- Year
- 2023
- Research Committee(s)
- Melanoma
- PMID
- PMID36856617
- Study Number(s)
- S1801